VivoSeq
Other

Apatinib

0

Pipeline Programs↗

1

Active Trials↗

2

Companies Involved↗

Apatinib is an early-stage landscape with 0 programs across 2 companies. The most active players are GSK, Novartis.

Intelligence

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

69/100

Attrition Rate

20/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

GSK logo

GSK

0 programs

PreclinicalNovartis logo

Novartis

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

20

clinical trials

Completed9 · 45%
Unknown status6 · 30%
Terminated3 · 15%
Withdrawn1 · 5%
Recruiting1 · 5%

Clinical Trials

Trial Activity

20 trials

Liposomal Irinotecan and Apatinib in ES-SCLC
Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT06749691·30 enrolled
Effect of Itraconazole on the Pharmacokinetics of Apatinib
Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 1·NCT02836171·20 enrolled
Rollover Study Of Lapatinib In Cancer Patients
Completed·GSK logoGSK·Phase 1·NCT00169533·31 enrolled
A Study in Cancer Patients to Evaluate the Bioequivalence of Alternative Formulations of Lapatinib
Completed·GSK logoGSK·Phase 1·NCT00996762·158 enrolled
DETECT III - A Multicenter, Phase III Study to Compare Standard Therapy +/- Lapatinib in HER2-ve MBC-Patients With HER2+ve CTCs
Completed·—·Phase 3·NCT01619111·105 enrolled
A Study in Cancer Patients to Evaluate the Effect of Lapatinib on the QTc Interval
Completed·GSK logoGSK·Phase 4·NCT01328054·58 enrolled
Effect of Rifampicin on the Pharmacokinetics of Apatinib
Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 1·NCT02836821·20 enrolled
A Food Effect Study of Apatinib Mesylate in Healthy Subjects
Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 1·NCT04341090·42 enrolled
Study Of Safety And Tolerability Of GW786034 Given With Lapatinib In Cancer Patients
Completed·GSK logoGSK·Phase 1·NCT00158782·75 enrolled
Lapatinib Plus Trametinib in KRAS Mutant NSCLC
Completed·TThe Netherlands Cancer Institute·Phase 1/2·NCT02230553·35 enrolled
PhII Neo-Adjuvant Letrozole & Lapatinib in Pts w/HER2+ & Hormone Receptor+ Operable Breast CA SPORE
Terminated·VVanderbilt-Ingram Cancer Center·Phase 2·NCT00499681·6 enrolled
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone
Terminated·Novartis logoNovartis·Phase 3·NCT00968968·37 enrolled
The Myocet/Lapatinib Study. ICORG 10-03, V5
Terminated·CCancer Trials Ireland·Phase 1/2·NCT01495884·11 enrolled
A Phase I Study to Test Alternate Oral Formulations vs the Current Tablet Formulation of Lapatinib
Withdrawn·GSK logoGSK·Phase 1·NCT00513253
A Phase II Study of Apatinib in STS Patients
Unknown status·SShanghai Jiao Tong University Affiliated Sixth People's Hospital·Phase 2·NCT03064243·53 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)